USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

50万美元的付款是Curasight A/S和Curium Inc.之间关于开发和商业化用于前列腺癌的uTRACE®的全球许可和合作协议下的第一个里程碑。

Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE® PET imaging technology

里程碑涉及成品GMP制造的验证，并说明了uTRACE®PET成像技术开发计划的进展

Under the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercialization

根据2023年签署的协议，Curasight有资格在开发里程碑中获得高达mUSD 70的开发里程碑，以及额外的商业里程碑，以及商业化后销售的两位数版税

COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ('Curasight' or 'the Company') – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer. The milestone relates to the validation of GMP manufacturing of finished product.

哥本哈根，2024年1月22日/PRNewswire/-Curasight A/S（“Curasight”或“公司”）-（股票代码：CURAS）今天宣布，根据与Curium inc.的协议，实现了第一个里程碑，开发Curasight的uTRACE®PET成像技术，以改进前列腺癌的诊断。该里程碑涉及成品GMP制造的验证。

.

.

The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023. Under the terms of the deal Curasight will develop its proprietary uTRACE® technology for use in prostate cancer until regulatory approval is granted in the EU and USA with Curium responsible for the commercial manufacture of uTRACE® and world-wide commercialization.

50万美元里程碑是2023年5月与Curium Inc.签署的协议中的第一个里程碑。根据协议条款，Curasight将开发其专有的uTRACE®技术用于前列腺癌，直到欧盟和美国获得监管部门的批准，并由Curium负责uTRACE®的商业制造和全球商业化。

Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization..

Curasight有资格在开发和商业里程碑中获得高达mUSD 70的版税，以及最终商业化后在主要市场销售的两位数百分比版税。。

'Reaching this milestone illustrates the strong progress being made under our agreement with Curium – a global leader in nuclear medicine and an expert in developing, manufacturing and commercializing world-class radiopharmaceutical products,' said Curasight's CEO Ulrich Krasilnikoff. 'Today's news is also a testament to the hard work and commitment of our team in pursuing our mission to use Curasight's uPAR theranostic platform to improve cancer treatment with more accurate diagnosis using uTRACE® and a more efficient, gentle, and targeted treatment with uTREAT®'.

Curasight首席执行官乌尔里希·克拉西尼科夫（UlrichKrasilnikoff）说：“达到这一里程碑表明，我们与库里姆（Curium）达成协议，取得了巨大进展。库里姆是核医学领域的全球领导者，也是开发、制造和商业化世界级放射性药物产品的专家。”今天的新闻也证明了我们团队的辛勤工作和承诺，我们的使命是使用Curasight的uPAR治疗诊断平台来改进癌症治疗，使用uTRACE®进行更准确的诊断，并使用uTREAT®进行更有效，温和和有针对性的治疗。

About the Phase 2 trial with uTRACE® in prostate cancer

关于uTRACE®在前列腺癌中的2期试验

The primary objective of the phase 2 trial is to investigate Curasight's first-in-class PET tracer, 64Cu-DOTA-AE105 as a non-invasive grading tool of prostate cancer patients that are followed in active surveillance. Patients in active surveillance are continuously monitored for changes in the aggressiveness of their prostate cancer and can be followed for years without identifying the need for treatment.

第二阶段试验的主要目的是研究Curasight的一流PET示踪剂64Cu-DOTA-AE105，作为前列腺癌患者的非侵入性分级工具，并进行主动监测。积极监测的患者会持续监测其前列腺癌侵袭性的变化，并且可以随访多年而不确定是否需要治疗。

The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with the US Food and Drug Administration (FDA).  The phase 2 trial is part of the development framework agreed under the deal with Curium.   .

试验设计来自uTRACE®的研究和早期研究，以及与美国食品和药物管理局（FDA）的协议讨论。第二阶段试验是根据与库仑的交易达成的发展框架的一部分。。

About the uPAR diagnostic platform

关于uPAR诊断平台

The uTRACE® platform is part of Curasights uPAR theranostic solution, made up of its uTRACE® diagnostic technology and its uTREAT® targeted treatment technology. In prostate cancer, uTRACE® is presently developed for diagnostic purposes only. Curasight's ambition is to develop both uTREAT® and uTRACE® to improve diagnosis and treatment solutions of certain cancers. .

uTRACE®平台是Curasights uPAR theranostic解决方案的一部分，由其uTRACE®诊断技术和uTREAT®靶向治疗技术组成。在前列腺癌中，uTRACE®目前仅用于诊断目的。Curasight的目标是开发uTREAT®和uTRACE®，以改进某些癌症的诊断和治疗解决方案。。

About Curium

关于Curium

Curium is a global leader in radiopharmaceuticals. Curium develops, manufactures, and distributes world-class radiopharmaceutical products to help patients around the globe. Their proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

Curium是放射性药物领域的全球领导者。Curium开发、制造和分销世界一流的放射性药物产品，以帮助全球患者。他们久经考验的传统与开创性的方法相结合，是提供创新、卓越和无与伦比服务的标志。

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET, and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually.  www.curiumpharma.com..

凭借遍布欧洲和美国的制造设施，Curium每年为1400多万患者提供SPECT，PET和治疗性放射性药物解决方案，用于威胁生命的疾病。www.curiumpharma.com。。

For more information regarding Curasight, please contact:Ulrich Krasilnikoff, CEOPhone: +45 22 83 01 60E-mail: [email protected]www.curasight.com

有关Curasight的更多信息，请联系：Ulrich Krasilnikoff，CEO电话：+45 22 83 01 60电子邮件：[受电子邮件保护]www.Curasight.com

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/19744/3912889/2552841.pdf

https://mb.cision.com/Main/19744/3912889/2552841.pdf

Curasight-press-release-Curium First Milestone

Curasight新闻稿Curium First Milestone